Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:

Number of patients requiring pars plana vitrectomy at week 7.

This study will enrol patients with diabetes who have already elected to undergo pars plana
 vitrectomy (eye surgery) to remove persistent vitreous haemorrhage (a complication of severe
 diabetic eye disease in which blood fills the inner cavity of the eye, obscuring the vision
 and preventing treatment to stop the bleeding). Those in the treatment arm will have an
 intravitreal injection of ranibizumab (Lucentis) at the same dose used for the treatment of
 neovascular (wet) age-related macular degeneration (a disease that has some features in
 common with diabetic eye disease).
 
 It is hypothesised that this will promote clearance of the vitreous haemorrhage and that
 this, in turn, may mean that some patients do not need to proceed to vitrectomy.